These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 6237859)

  • 1. [Drug targeting with allogeneic IgG in patients with disseminated neuroblastoma].
    Melino G; Hobbs JR; Forrest DM; Castello MA
    Clin Ter; 1984 Aug; 110(3):203-8. PubMed ID: 6237859
    [No Abstract]   [Full Text] [Related]  

  • 2. Chylous effusions due to neuroblastoma resolved by intrapleural chlorambucil coupled to father's antibodies.
    Melino G; Tabara ZB; Hobbs JR
    J Pediatr Surg; 1985 Apr; 20(2):179-81. PubMed ID: 4009365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-complement killing of neuroblastoma cells.
    Gee AP; Van Hilten J; Graham-Pole J; Boyle MD
    Prog Clin Biol Res; 1985; 175():471-83. PubMed ID: 3991742
    [No Abstract]   [Full Text] [Related]  

  • 4. Distribution of natural antibody against human neuroblastoma among children with or without neuroblastoma.
    Fukuda M; Nozaki C; Ishiguro Y; Horibe K
    Med Pediatr Oncol; 2001 Jan; 36(1):147-8. PubMed ID: 11464870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.
    Cheung NK; Guo HF; Heller G; Cheung IY
    Clin Cancer Res; 2000 Jul; 6(7):2653-60. PubMed ID: 10914706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural antibody against neuroblastoma among Japanese children with or without neuroblastoma.
    Fukuda M; Nozaki C; Ishiguro Y; Horibe K
    Cancer; 1999 Nov; 86(10):2166-70. PubMed ID: 10570448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro effects of tumour specific antibodies with chlorambucil.
    Davies DA; O'Neill GJ
    Br J Cancer Suppl; 1973 Aug; 1():285-98. PubMed ID: 4548355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study.
    Cheung NK; Kushner BH; Yeh SJ; Larson SM
    Prog Clin Biol Res; 1994; 385():319-28. PubMed ID: 7972227
    [No Abstract]   [Full Text] [Related]  

  • 10. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome.
    Korfei M; Fühlhuber V; Schmidt-Wöll T; Kaps M; Preissner KT; Blaes F
    J Neuroimmunol; 2005 Dec; 170(1-2):150-7. PubMed ID: 16203043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
    Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum inhibitors of cellular immunity in human neuroblastoma. IgG subclass of blocking activity.
    Jose DG; Skvaril F
    Int J Cancer; 1974 Feb; 13(2):173-8. PubMed ID: 4856316
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of drug-antibody conjugates in the treatment of human myelosarcomas transplanted in nude mice.
    Latif ZA; Lozzio BB; Wust CJ; Krauss S; Aggio MC; Lozzio CB
    Cancer; 1980 Mar; 45(6):1326-33. PubMed ID: 6928397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells.
    Barker E; Reisfeld RA
    Cancer Res; 1993 Jan; 53(2):362-7. PubMed ID: 8417829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
    Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R
    J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological approach to the treatment of acute lymphoblastic leukemia.
    Bergolz VM; Kisljak NS; Eremeev VS; Rumjantzev AG; Akimova GV; Osipov SG
    Neoplasma; 1980; 27(4):355-61. PubMed ID: 6935532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-based immunotherapy in high-risk neuroblastoma.
    Johnson E; Dean SM; Sondel PM
    Expert Rev Mol Med; 2007 Dec; 9(34):1-21. PubMed ID: 18081947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine neuroblastoma cured in vivo by an antibody-dependent cellular cytotoxicity reaction.
    Byfield JE; Zerubavel R; Fonkalsrud EW
    Nature; 1976 Dec 23-30; 264(5588):783-5. PubMed ID: 1012319
    [No Abstract]   [Full Text] [Related]  

  • 19. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
    Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
    Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen.
    David K; Ollert MW; Vollmert C; Heiligtag S; Eickhoff B; Erttmann R; Bredehorst R; Vogel CW
    Cancer Res; 1999 Aug; 59(15):3768-75. PubMed ID: 10446994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.